antiviral agent 8

Antiviral agent 8, surpassing lead compounds crocin-1 and crocin-2, has been identified as a potent and promising candidate with enhanced antiviral activities.

2H-Pyrido[2',1':3,4]pyrazino[1,2-b]indazole-3-carboxylic acid, 6-(1, 1-Dimethylethyl)-6, 7-Dihydro-10 -(3-methoxypropoxy)-2-oxo-, (6R)- has antibacterial and antiviral activity and can be used to study Hepatitis B virus.

Antiviral agent is thiazolidin-4-one with anti-hepatitis B activity

Antiviral agent 34 is an orally available, potent antiviral compound that inhibits influenza A and B viruses.Antiviral agent 34 inhibits the proliferation of influenza viruses by modulating RNA polymerase.Antiviral agent 34 is used in the study of viral infections.

Antiviral agent 17 is a nucleoside analog with antiviral and antiparasitic activity, inhibits hepatitis C virus 1B and inhibits Trypanosoma brucei and Trypanosoma brucei, and can be used in the study of viral infections and malignant diseases.

Antiviral agent 27 (Compound 12) exhibits significant activity against the Ebola virus, with an EC50 value of 14 nM [1].

Antiviral agent 33 (compound 1c), a double-stranded DNA (dsDNA) virus inhibitor, exhibits potent inhibitory activity with IC50 values of 0.0790 µM for VACV and 0.1572 µM for AdV5, and is a candidate for oral administration [1].

Antiviral agent 36 (compound 27), a potent inhibitor of both dengue (DENV) and Zika (ZIKV) viruses, demonstrates replication inhibition with EC50 values of 100 nM for ZIKV-FLR, 90 nM for ZIKV-HN16, 210 nM for DENV-2, and 120 nM for DENV-3 [1].

Antiviral agent 7 is a peptide-based coating that kills viruses.

Anti-inflammatory agent 8 (compound 13) designated as an anti-inflammatory agent 8, displays enhanced activity on the COX-2 enzyme compared to COX-1, with an IC50 value of 0.09 nM. Furthermore, anti-inflammatory agent 8 exhibits oral bioavailability [1].

Antiparasitic agent-8 (Compound 9) exhibits potent antiparasitic activity against Hymenolepis nana, while demonstrating low levels of cytotoxicity [1].

Antiviral agent 14 is an antiviral agent that inhibits tobacco mosaic virus (TMV) (EC50: 135.5 μg/mL), and cucumber mosaic virus (CMV) (EC50: 178.6 μg/mL).

Antiviral agent 20 (Compound 17b) is a selective inhibitor of Zika virus (EC50: 4.5 μM) and exhibits low cytotoxicity.

Anti-MRSA Agent 8 (Compound 7g), a derivative of DAPG, exhibits potent antibacterial properties by interacting with bacterial cell membranes and is useful for studying methicillin-resistant Staphylococcus aureus (MRSA) [1].

Antimalarial agent 8 (Compound 7e) is a novel, orally active antimalarial agent that is effective against P. falciparum in vitro and effective orally in an in vivo mouse model of malaria (40 mg/kg).

Antitrypanosomal agent 8 (compound 3b) showed a strong antitrypanosomal effect against Trypanosoma brucei (IC50: 0.79 μM). The IC50 value was 80.95 μM.

Antileishmanial agent-8 (compound 18) shows potent and selective activity against Leishmania donovani ( L. donovani ) (IC50 = 5.64 μM) with relatively low cytotoxicity in L-6 cells (IC 50 =73.9 μM) [1].

Antituberculosis agent-8 is an antitubercular compound effective against M. tuberculosis H37Rv, demonstrating a minimum inhibitory concentration (MIC) of 3.53 μM (1.6 μg/mL). Additionally, it exhibits potent antifungal properties against A. niger, with an MIC of 62.50 μM.

Antiviral Agent 23, an effective inhibitor of enterovirus 71 (EV71) with an EC50 value of 94 nM, also exhibits potent suppression of METTL3/METTL14 activity. This compound is employed in the research of infections.

Antiviral agent 25 (compound 6g), a novel non-peptide analog covalent inhibitor of SARS-CoV-2 3CL pro, exhibits robust inhibitory activity against both SARS-CoV-2 3CL pro and SARS-CoV-2 PL pro, with IC50 values of 0.118 µM and 0.448 µM, respectively. Furthermore, it demonstrates significant antiviral effects against SARS-CoV-2, achieving an EC50 value of 7.249 µM [1].

Antiviral agent 10 effectively inhibits the respiratory syncytial virus (RSV) [1], serving as a potent anti-viral compound.

Antiviral agent 18 (Compound 5) shows good antiviral activity against murine norovirus. Antiviral agent 18 is an anti-infection agent that has the potential in infectious and malignant diseases research [1].

Antiviral agent 19 (Compound 3) is a selective inhibitor of Zika virus (EC50: 1.3 μM) with low cytotoxicity.

GABAA receptor agent 8 (compoud 5e) has the potential in epilepsy research. GABAA receptor agent 8 is a potent positive modulator of GABAA receptor with anticonvulsant activity both in vitro and in vivo as well as low neurotoxicity [1].

Antiviral agent 43 (compound 16) serves as a potent, orally active inhibitor of influenza A virus entry, demonstrating efficacy by inhibiting the replication of the influenza A strains VH04-H5N1 and PR8-H1N1 with EC50 values of 240 nM and 72 nM, respectively [1].

Antiviral agent 5 is a crucial intermediate utilized in the development of antiviral agents that specifically target 3C and 3CL proteases, which includes the SARS-CoV-2 M pro enzyme.

Antiviral agent 9 exhibits potent efficacy against HIV-1 with an EC50 value of 0.006 nM, indicating extremely low concentrations are sufficient to inhibit the virus. Additionally, it demonstrates a selectivity index (SI) nearly 300 times higher than that of tenofovir alafenamide fumarate (TAF), outlining its superior selectivity and potential safety profile.

Antiviral agent 6 showed excellent anti-TSWV effects in vivo (EC50: 188 mg/L).

Antiviral Agent 30 (Example 118) is an active compound against HCV and RSV with an inhibitory concentration (IC 50) of greater than 25μM [1].

Antiproliferative agent-8 (Compound 5a) is an anti-cancer compoundwith antiproliferative activity. Antiproliferative agent-8 can significantly increase the P53 levels.

Nucleoside Derivatives - 6-Modified purine nucleosides; Drugs and Inhibitors

Antiviral agent 15 (Compound 15f) is a Clofazimine derivative with antiviral activity.Antiviral agent 15 inhibits rabies virus (EC50: 1.45 μM) and pseudotyped SARS-CoV-2 (EC50: 14.6 μM).

Antiviral agent 35 (compound 4d) serves as a potent orally active inhibitor of the influenza virus, targeting early stages of viral replication. It suppresses influenza-induced ROS accumulation, autophagy, and apoptosis, along with the inflammatory response mediated by the RIG-1 pathway in a mouse model of pulmonary infection. Its cytotoxicity is minimal in MDCK cells, displaying a CC50 greater than 800 μM, and possesses anti-H1N1 (A/Weiss/43) activity with an EC50 of 2.28 μM [1].

Antiviral agent 46, also known as compound 4, is a cannabidiol (CBD) derivative exhibiting anti-SARS-CoV-2 activity (IC50: 1.90 μM) and ACE2 inhibition (IC50: 1.37 μM) [1].

Antimicrobial Agent-8 exhibits a high level of antimicrobial efficacy, demonstrating a minimum inhibitory concentration (MIC) range of 2-8 μg/mL against both Gram-negative and Gram-positive bacteria. Furthermore, this compound also possesses anti-inflammatory properties, effectively combating lipopolysaccharide-induced inflammation.

Antioxidant agent-8 is an orally active compound that inhibits the deposition of Aβ 1-42 by preventing fibril aggregation (IC 50 =11.15 µM) and aiding in fibril disaggregation (IC 50 =6.87 µM). Moreover, it effectively counters Cu2+-induced Aβ 1-42 fibril aggregation and disaggregation, exhibiting lower IC 50 values of 3.69 µM and 3.35 µM, respectively. This compound also possesses antioxidant and anti-inflammatory activities, demonstrates biosafety and blood-brain barrier permeability, and offers a neuroprotective effect.

SARS-CoV-2 Mpro-IN-8 (compound 6b) is an antiviral agent effective against SARS-CoV-2 [1].

Carbodine (Carbocyclic cytidine) is a broad-spectrum antiviral agent and targets CTP synthetase that converts UTP to CTP. It possesses significant antiviral activity against influenza virus types A0/PR-8/34 and A2/Aichi/2/68 in vitro.

Ganciclovir (BW 759) hydrate is a nucleoside analogue that is an orally active antiviral agent with anti-cytomegalovirus activity. Ganciclovir hydrate is also active against members of the herpes group and some other DNA viruses in vitro. Ganciclovir hydrate inhibits the replication of human herpes viruses (HSV 1 and 2, CMV) and adenovirus serotypes 1, 2, 4, 6, 8, 10, 19, 22 and 28 in vitro. Ganciclovir hydrate also has an IC 50 of 5.2 μM against feline herpesvirus type-1 ( FHV-1 ) and can diffuse into the brain [1] [2] [3].

Arbidol-d6 Hydrochloride is a deuterated compound of Arbidol Hydrochloride. Arbidol Hydrochloride has a CAS number of 131707-23-8. Arbidol (Umifenovir) hydrochloride, an broad-spectrum antiviral chemical agent, can inhibit cell invade of enveloped viruses by blocking viral fusion with host cell membrane.

Arbidol (Umifenovir) is an orally active broad-spectrum antiviral compound that is a fusion inhibitor and interacts with the SARS-CoV-2 spicule protein.Arbidol shows inhibitory activity against a variety of coronaviruses.Arbidol has anti-inflammatory and antioxidant activity and may be useful for the study of concentrated infections.

Umifenovir hydrochloride (Arbidol HCl) , an broad-spectrum antiviral chemical agent, can inhibit cell invade of enveloped viruses by blocking viral fusion with host cell membrane.